Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire-Impax ADHD generic dispute continues
Shire previously announced a pending suit against Impax based on Impax’s notice letter for a 30mg generic version of Adderall XR. Shire has now filed a second complaint
Shire previously announced a pending suit against Impax based on Impax’s notice letter for a 30mg generic version of Adderall XR. Shire has now filed a second complaint
The first gene, involved in copying DNA, was linked specifically to pancreatic and ovarian cancers, which are notoriously hard to diagnose at an early stage. It could help
A longstanding problem has been to isolate an infectious agent that is present in our tissues that could stimulate the development of atherosclerotic plaques. Until recently, no single
“While it is important that we correct false assertions about how Lilly manages its data, it is even more important to set the record straight for patients who
The antibody was created using Abgenix’s proprietary XenoMouse technology and is the 11th antibody generated with Abgenix’s technology to move into the clinic phase. “We are pleased to
The agreement, previously announced by both companies on November 8, 2004, became effective after all conditions were satisfied, including expiration of the waiting period required under the Hart-Scott-Rodino
The trial was carried out in 1,349 healthy subjects aged 18 to 64, in 28 Canadian sites, between October 2003 and May 2004. Both one- and two-dose FluINsure
Results of the first study ever to assess efficacy across all symptoms commonly experienced during a migraine attack found that treatment with Zomig (zolmitriptan) nasal spray produced a
Pexeva is a branded selective serotonin reuptake inhibitor for the treatment of depression, obsessive/compulsive disorder, and/or panic disorder. Pexeva was launched by Synthon in February 2004, and is
Mylan’s vice chairman and CEO, Robert Coury, explained that King’s restating of its financial results for 2002, 2003 and the first half of 2004, violates the merger agreement.